Underweight MDLZ at $63.53: trim 25%, retain 75-85% core with $57.88 structural stop
Three-way analyst convergence on Underweight with low-end trim (~25%) preferred over higher ranges (25-35% aggressive, 30-40% conservative) because marginal utility of additional trimming is small versus meaningful upside sacrifice; $57.88 stop (200 SMA) preferred over $60.74 (10 EMA minus 1 ATR) to avoid whipsaw in low-beta name; retained 75-85% position justified by structural floor (Oreo/Cadbury/Toblerone moat, intact bullish MA stack, real FCF generation) but doesn't warrant adding; asymmetry favors trim as full-size hold requires five independent variables (oil, cocoa, FDA, FX, 19x multiple) to cooperate while trim only requires structural floor breach for downside capture.
| Position | Action |
|---|---|
| Current levels ($63.53) | Trim ~25% of position |
| Post-trim retained position | Run at 75-85% of normal target weight |
| Structural floor breach below $57.88 (200 SMA) | Full exit of retained position |
MDLZ is materially undervalued at $63.53 with a forward PE of 18.9x expecting EPS to double, supported by bullish technicals, a 3.22% dividend yield, strong pricing power on iconic brands, and a fortress balance sheet with negative working capital as a structural competitive advantage.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 62.33 | bullish |
| close_50_sma | 60.98 | bullish |
| close_200_sma | 57.88 | bullish |
| rsi | 58.93 | neutral |
| macd | 0.58 | bullish |
| macdh | +0.04 | bullish |
| boll_ub | 64.42 | neutral |
| atr | 1.59 | neutral |
Support: 62.33 · 60.98 · 59.26 · 57.88 | Resistance: 64.42 · 64.99
MDLZ shows a fully bullish technical profile with price ($63.53) above all moving averages in a "golden stack" formation. RSI (58.93) is in neutral-to-bullish territory leaving upside room, while MACD (0.58) holds above signal (0.54) with thin positive histogram (+0.04), indicating digestion rather than euphoria. Price sits in the upper third of its Bollinger range (59.26–64.42) with key resistance at $64.42 (Bollinger UB) and $64.99 (July swing high). Support zones are identified at 10 EMA $62.33, 50 SMA $60.98, and major 200 SMA $57.88. Action bias is HOLD with bullish lean; buy on pullback to 10 EMA or breakout above $64.42 on volume ≥7M.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Flush into $58.00-$59.00 zone holding 200 SMA with stable margins and free cash flow
Then: Re-engage/add to position
↩ rebuts: “Bear's 'wait for pullback' thesis”
EV: +$66.65 retest near-term; $70+ within 12 months · concedes: Oil cost pressure is a valid input cost headwind, though historically passable via pricing power; FDA additive risk is sector-wide ambient risk, not company-specific
MDLZ's "asymmetric" setup is actually a trap: the stock requires flawless execution across five independent variables while technicals show distribution and the dividend is being funded by capital, not earnings.
· concedes: MACD histogram still technically positive at +0.04; Dividend yield of 3.22% is attractive on a nominal basis; MDLZ has decades of pricing power; Goodwill of $24.23B is largely intact on the balance sheet
→ vs conservative: Dividend yield of 3.22% is framed as a shield but actually exposes holders to multiple compression risk; a re-rating from 19x to 16x forward earnings wipes out 2.5 years of dividends
→ vs conservative: Waiting for pullback to 50-day MA at 61 or 200-day at 58.60 risks either missing the dip entirely if inputs keep ripping, or adding to a heavier position at worse optics if earnings disappoint
→ vs neutral: Tate's 2.5x category growth is the reason MDLZ is at current levels, not a future catalyst; new marginal buyers need something not already in consensus
→ vs neutral: Framing MDLZ as a 'core defensive holding' can cause a 5% position to become a 15% drawdown; defensive doesn't mean invulnerable
→ vs neutral: Rate tailwind is exhausted - Polymarket shows 86% probability of zero rate cuts in 2026, eliminating multiple expansion potential
Market Cap
$81.08B
Current Price
~$63.17
52-Week High
$66.65
52-Week Low
$51.20
50-Day Moving Avg
$61.12
200-Day Moving Avg
$58.64
PE Ratio (TTM)
38.74x
Forward PE
18.90x
PEG Ratio
1.03
Price to Book
3.05x
Beta
0.404
Dividend Yield
3.22%
EPS (TTM)
$1.64
Forward EPS
$3.36
Revenue TTM
$39.67B
Gross Profit TTM
$12.36B
EBITDA TTM
$6.08B
Net Income TTM
$3.52B
Q1 2025 Revenue
$9,313M
Q1 2025 Gross Profit
$2,430M
Q1 2025 Operating Income
$682M
Q1 2025 Net Income
$402M
Q1 2025 Diluted EPS
$0.31
Q2 2025 Revenue
$8,984M
Q2 2025 Gross Profit
$2,937M
Q2 2025 Operating Income
$1,174M
Q2 2025 Net Income
$641M
Q2 2025 Diluted EPS
$0.49
Q3 2025 Revenue
$9,744M
Q3 2025 Gross Profit
$2,612M
Q3 2025 Operating Income
$785M
Q3 2025 Net Income
$743M
Q3 2025 Diluted EPS
$0.57
Q4 2025 Revenue
$10,496M
Q4 2025 Gross Profit
$2,956M
Q4 2025 Operating Income
$952M
Q4 2025 Net Income
$665M
Q4 2025 Diluted EPS
$0.51
Q1 2026 Revenue
$10,080M
Q1 2026 Gross Profit
$2,803M
Q1 2026 Operating Income
$860M
Q1 2026 Net Income
$560M
Q1 2026 Diluted EPS
$0.40
Total Assets
$71.12B
Goodwill + Intangibles
$43.76B
Net PPE
$11.29B
Total Equity
$25.75B
Total Debt
$21.62B
Net Debt
$19.50B
Cash & Equivalents
$1.52B
Current Ratio
0.60
Working Capital
-$10.76B
Tangible Book Value
-$18.01B
Debt to Equity
82.6%
Net Debt / TTM EBITDA
3.2x
Q1 2025 Operating CF
$1,092M
Q2 2025 Operating CF
$308M
Q3 2025 Operating CF
$717M
Q4 2025 Operating CF
$2,397M
Q1 2026 Operating CF
$467M
Q1 2025 CapEx
$277M
Q2 2025 CapEx
$305M
Q3 2025 CapEx
$299M
Q4 2025 CapEx
$398M
Q1 2026 CapEx
$312M
Q1 2025 FCF
$815M
Q2 2025 FCF
$3M
Q3 2025 FCF
$418M
Q4 2025 FCF
$1,999M
Q1 2026 FCF
$155M
TTM FCF
~$2.25B
Q1 2025 Dividends Paid
$623M
Q2 2025 Dividends Paid
$610M
Q3 2025 Dividends Paid
$609M
Q4 2025 Dividends Paid
$645M
Q1 2026 Dividends Paid
$644M
Annualized Dividends
~$2.51B
Q1 2025 Buybacks
$1,522M
Q2 2025 Buybacks
$131M
Q3 2025 Buybacks
$240M
Q4 2025 Buybacks
$492M
Q1 2026 Buybacks
$0
Annualized CapEx
~$1.3B
CapEx as % Revenue
3.3%
FCF Conversion
~64%
Gross Margin (TTM)
31.1%
Operating Margin
22.0%
Net Margin
8.9%
EBITDA Margin
15.3%
ROE
13.3%
ROA
4.1%
Goodwill
$24.23B
Interest Expense
~$150M/quarter
Normalized Q1 2026 Earnings
~$597M
Q1 2026 Impairment Charges
$52M
Operating CF TTM
~$4.88B
Strengths
Concerns
HOLD — MDLZ is a high-quality, defensive compounder with a reliable 3.22% dividend yield, stable cash generation (~$2.25B TTM FCF), and reasonable forward valuation (18.9x forward PE). The stock is trading near 52-week highs with limited margin of safety, and the depressed trailing EPS ($1.64 TTM vs. $3.36 forward) makes headline valuation metrics appear stretched. Existing positions are warranted as a core defensive holding; new capital should await a pullback toward the 50-day MA (~$61) or 200-day MA (~$58.60) before adding exposure, pending execution on the implied earnings recovery.
Macro: The macro backdrop is predominantly constructive: the S&P 500 closed at a record high with risk-on sentiment, the soft-landing narrative is entrenched with only 8% recession odds, and disinflation continues with inflation above 4.5% at just 18% probability. However, a higher-for-longer rate environment is fully priced in at 86% no-cut probability for 2026, and energy costs present a significant headwind with oil up 86% YTD. The Fed rate path and oil trajectory represent the primary macro risks and opportunities for MDLZ's 2H26 outlook.